Cytovale vs Noom
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cytovale is developing a rapid point-of-care sepsis diagnostic — IntelliSep — that measures immune cell deformability via microfluidics to detect sepsis in ~8 minutes; received FDA Breakthrough Device Designation; raised $88M total;
About
Cytovale is a medical technology company headquartered in San Francisco, California, founded in 2014 by Lydia Sohn and others, with roots in biophysics research at the University of California, Berkeley. The company is developing the IntelliSep test — a rapid, near-patient diagnostic for sepsis that uses a proprietary microfluidic technology to measure the mechanical properties (deformability) of immune cells in whole blood. Sepsis — a life-threatening systemic immune response to infection — kills approximately 270,000 Americans annually and is the leading cause of hospital mortality, yet current diagnostic approaches (blood cultures, lactate, clinical scoring systems) are slow, non-specific, and frequently fail to identify sepsis before it progresses to organ failure and septic shock.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
About
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.